A new analytical novel RP-HPLC method development and validation for the quantitative determination of Dasatinib in pure form and marketed pharmaceutical dosage form
Authors
Article Information
Publication Timeline
- Published
Abstract
The present work includes a simple, economic, rapid, accurate and precise isocratic RP-HPLC method development for estimation of Dasatinib in bulk form and its marketed formulation. Estimation was done at 286nm which was found to be λmax of Dasatinib. The simple, selective, isocratic RP-HPLC method for Dasatinib was developed on Phenomenex Luna (C18) RP Column; 250 mm x 4.6 mm, 5µm with a mobile phase of Phosphate Buffer (pH-4.6) and Methanol were taken in the ratio of 65:35% v/v at a flow rate of 1.0 ml/min and detection wavelength 286nm. The developed method was validated successfully according to ICH Q2 (R1) guidelines. The chromatographic methods showed a good linear response with r2 values of 0.9995. The percentage relative standard deviation for method was found to be less than two, indicating that the methods were precise. The mean percentage recovery was for RP-HPLC method was 100.437%. From the results it could be concluded that both the developed method was specific, selective and robust. The method could be successfully applied for analysis of Bulk form and Marketed formulation of Dasatinib.
How to Cite
Iram, S., Nuthana, Y., Shireesha, M., Teja, K. S., & Chary, S. S. (2024). A new analytical novel RP-HPLC method development and validation for the quantitative determination of Dasatinib in pure form and marketed pharmaceutical dosage form. International Journal of Medical and All Body Health Research, 5(2), 31-37.
Iram, Sumera, et al. "A new analytical novel RP-HPLC method development and validation for the quantitative determination of Dasatinib in pure form and marketed pharmaceutical dosage form." International Journal of Medical and All Body Health Research, vol. 5, no. 2, 2024, pp. 31-37.
Iram, S., Nuthana, Y., Shireesha, M., Teja, K. S. and Chary, S. S. (2024) 'A new analytical novel RP-HPLC method development and validation for the quantitative determination of Dasatinib in pure form and marketed pharmaceutical dosage form', International Journal of Medical and All Body Health Research, 5(2), pp. 31-37.
Iram S, Nuthana Y, Shireesha M, Teja KS, Chary SS. A new analytical novel RP-HPLC method development and validation for the quantitative determination of Dasatinib in pure form and marketed pharmaceutical dosage form. International Journal of Medical and All Body Health Research. 2024;5(2):31-37.
Similar Articles
- Formulation and evaluation of gastroretentive floating microspheres of nimodipine Vol 5, Issue 2 (2024)
- Effect of Vitamin E V/S Vitamin C application on wound healing in the gingival depigmentation procedure: A split-mouth clinical comparative study Vol 5, Issue 2 (2024)
- Formulation and evaluation of metoprolol tartrate transdermal drug patches Vol 5, Issue 2 (2024)
- RP-HPLC Method Development and Validation for the Quantitative Determination of Ruxolitinib in Pure Form and Marketed Pharmaceutical Dosage Form Vol 5, Issue 2 (2024)
- Ntoum: A major focus of malaria in Gabon's Estuary province Vol 5, Issue 2 (2024)
Find this Article on
Google Scholar Semantic Scholar OpenAlex ResearchGate BASEA newly published article may take a few days to appear on these services.